Quantbot Technologies LP Buys $1.46M Stake in Vertex Pharmaceuticals

The hedge fund added 3,727 shares of the biotech company in Q3 2025.

Published on Mar. 6, 2026

Got story updates? Submit your updates here. ›

Quantbot Technologies LP, a Boston-based hedge fund, disclosed in a regulatory filing that it bought a new position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the third quarter of 2025. The fund purchased 3,727 shares of the pharmaceutical company's stock, valued at approximately $1.46 million.

Why it matters

Vertex Pharmaceuticals is a leading biotech company focused on developing treatments for serious diseases, particularly cystic fibrosis. The company's portfolio of CFTR modulators has transformed standards of care for many CF patients. Quantbot's investment in Vertex reflects the hedge fund's belief in the company's growth potential and pipeline.

The details

According to the filing, Quantbot Technologies LP bought the 3,727 shares of Vertex Pharmaceuticals in the third quarter. The purchase was part of the hedge fund's strategy to invest in promising pharmaceutical and biotech companies.

  • Quantbot Technologies LP disclosed the new position in a regulatory filing on March 6, 2026.

The players

Quantbot Technologies LP

A Boston-based hedge fund that invests in a variety of sectors, including pharmaceuticals and biotechnology.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on developing therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Quantbot's investment in Vertex Pharmaceuticals reflects the hedge fund's confidence in the biotech company's ability to continue developing innovative treatments for cystic fibrosis and other serious diseases. As Vertex's pipeline progresses, investors will be closely watching the company's performance and potential for future growth.